IXICO plc announced that an existing client has contracted IXICO to provide imaging services for the extension study of their Huntington's disease ('HD') Ph2b trial. This is a new study protocol and results in a new work order worth just under £2 million which IXICO expects to deliver over the next 4 years.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.125 GBX | 0.00% | -7.14% | -35.00% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-35.00% | 4.91M | |
+26.28% | 42.68B | |
-3.99% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+6.36% | 24.94B | |
-21.47% | 18.96B | |
+27.58% | 12.3B | |
-2.75% | 11.95B | |
-2.02% | 11.55B |
- Stock Market
- Equities
- IXI Stock
- News IXICO plc
- IXICO plc Announces Contract Win in Huntington's Disease